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Abstract
Purpose: To evaluate the effect of Mydrane (contains tropicamide, phenylephrine hydrochloride, and lidocaine
hydrochloride) on time needed to induce mydriasis and mydriasis stability during cataract surgery.
Methods: This was an observational, non-interventional, multicenter study of patients undergoing cataract
surgery who received Mydrane for mydriasis and intraocular anesthesia. The study was conducted at seven
ophthalmology departments at university hospitals in Poland. Patients admitted for cataract surgery within a
2-week period were asked to participate in the study. Patients whose pupils dilated to a diameter ‡6 mm after
topical mydriatic administration during preoperative examinations were scheduled to receive Mydrane and
included in the registry. No additional inclusion criteria were used. Patients’ medical histories, examination
results, and operative details were recorded. Pupil diameter was measured during surgery. Surgeons were asked
to complete a Likert-based survey in parallel.
Results: A total of 307 patients were enrolled. The mean pupil diameter was 7.0 – 1.0 mm before capsulorhexis
and 6.9 – 1.2 mm before lens implementation. A pupil diameter ‡6 mm was achieved in 91.9% and 87.6% of
patients before capsulorhexis and lens implantation, respectively. We asked 58 surgeons whether they agreed
with the statement ‘‘Mydriasis was obtained in a short time after the administration of Mydrane’’; the surgeons
agreed with this statement after 92.2% (283/307) of surgeries. In addition, after 88.2% of surgeries, the surgeons
agreed with the statement ‘‘Mydriasis was stable after the administration of Mydrane.’’
Conclusions: Mydriasis was rapidly and stably obtained after Mydrane injection, as demonstrated by pupil
diameter measurements during surgery and surgeons’ feedback.
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Introduction
Adequate and stable pupil dilatation is a key el-ement of cataract surgery. Thus far, topical mydriatic
eye drops or inserts have served as the standard method for
achieving pupil dilatation during cataract surgery. Behndig
et al.1 described the advantages and limitations of these
methods and summarized many of the approaches used for
achieving pupil dilation that have been studied during the
past 30 years.2 We have observed increases in the use of
intracameral mydriatics in contemporary ophthalmology.3–5
In 2015, the first ready-to-use, standardized, commercially
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manufactured medicinal product Mydrane (Laboratoires
Thea, France) was approved for use in several European
countries, including Poland.6 The product is injected into
the anterior chamber at the beginning of cataract surgery
to induce mydriasis and intraocular anesthesia. One 0.2-mL
dose contains 0.04 mg of tropicamide, 0.62 mg of phenyl-
ephrine hydrochloride, and 2 mg of lidocaine hydrochloride.
Mydrane is a salt- and pH-balanced solution.
Data from a phase III clinical trial have shown that My-
drane:
 induces stable mydriasis within a very short time and
has a good safety profile,
 allows for reductions in doses of active substances
compared with eye drops,
 speeds up surgery preparation because it is administered
once at the beginning of surgery and does not need to be
administered during the preoperative period.7
This study was a well-controlled trial whose rigorous in-
clusion and exclusion criteria may have prevented the re-
sults from being generalized to the entire population of
patients undergoing cataract surgery. Our observational,
investigator-initiated trial involved patients receiving My-
drane under conditions to which actual populations of
patients undergoing cataract surgery are subjected. To our
knowledge, this was the first observational, multicenter
study to assess this ready-to-use product. A new study from
a single center assessed pupil diameter during surgery and
visual acuity postoperatively; however, this study utilized
different measurement points and assessed outcomes based
on patient feedback rather than surgeon feedback.8
Methods
Study design
This was an observational, non-interventional, multicen-
ter registry of patients undergoing cataract surgery who
received Mydrane to induce mydriasis and intraocular an-
esthesia during surgery. According to the definition given
in the ‘‘Registries for Evaluating Patient Outcomes: A
User’s Guide. Third Edition,’’ ‘‘a patient registry is an or-
ganized system that uses observational study methods to
collect uniform data (clinical and other) to evaluate speci-
fied outcomes for a population defined by a particular dis-
ease, condition, or exposure, and that serves one or more
predetermined scientific, clinical, or policy purposes.’’9
Surgeon opinions were collected in parallel. The operating
surgeon’s opinions on the times required to induce mydriasis
and achieve mydriasis stability were measured on a 5-point
Likert scale immediately after the end of the surgery.10
The study was designed, performed, and reported in
accordance with the ethical principles discussed in the
Declaration of Helsinki and the Strengthening the Reporting
of Observational Studies in Epidemiology guidelines.11 The
study was an Investigator Initiated Trial approved by the
Ethics Committee of Warsaw Medical University (Warsaw,
Poland), number AKBE/17/2017.
To ensure that our data were of the best quality, we allowed
the study to be monitored by an independent local Clinical
Research Organization (CRO) with experience in the con-
duction and monitoring of clinical trials (4 Medicine Rek PLL,
Warsaw, Poland), according to the decision of heads of the
ophthalmology departments leading the research.
Patient selection
All patients admitted for cataract surgery that was per-
formed by surgeons affiliated with the seven ophthalmology
departments participating in the study within a 2-week pe-
riod in March 2017 were informed about our research.
Those who consented to participate in the study were in-
cluded herein. The patient selection procedure was not bi-
ased, because the lists of patients who underwent surgery
during the study period were created before the decision
regarding the performance of the study was made, in ac-
cordance with organizational policies regarding the perfor-
mance of cataract surgeries in public hospitals in Poland.
According to the Summary of Product Characteristics,
‘‘Mydrane should only be used in patients who have dem-
onstrated, at a previous visit, a satisfactory pupil dilation
with topical mydriatic therapy.’’12 While designing the
study, the investigators agreed that sufficient pupil dilation
during the preoperative visit would be defined as pupil di-
lation to a diameter ‡6 mm, as measured as described in the
protocol. The 6-mm cut-off value was adopted because the
Lens Opacities Classification System III (LOCS III) scale,
which is used to assess cataract maturity, requires that the
pupils are dilated to a diameter ‡6 mm.13 Therefore, patients
in whom pupil dilation to a diameter ‡6 mm (1 mm smaller
during preoperative assessment than in Labetoulle’s study)
was achieved during the preoperative visit were eligible to
receive Mydrane. The LOCS III was used with the consent
of Chylack, Inc. (Durham, NC).
Patient evaluation
Data were collected with an electronic case report form
(CRF) with the MedPhantom system, which was provided
by 4 Medicine Rek PLL (Warsaw, Poland). Only data per-
taining to the eyes that were operated on during the study
were collected. During the first visit (visit 1), demographic
data and data regarding eye diseases, previous eye surgeries
(including laser therapy), general diseases, and current
ophthalmic and general medications were recorded. All
patients underwent a full preoperative assessment (corrected
distance and near visual acuity assessment, slit-lamp eval-
uation, dilated fundoscopic examination, biometry, Ultra-
sound (USG), and corneal endothelial cell count, according
to the routine practices of each hospital). As iris color may
influence mydriasis, iris color was assessed according to the
simplified anthropological Martin scale.14
The pupil diameter assessment that was completed during
the preoperative visit was performed with a device used for
pupil diameter measurements, according to the instructions
provided by the manufacturer. The instruments used in this
study included a Volk Eye Check with a grid scale (Volk
Optical, Inc., Mentor, OH), a Pupilometer Neuroptics
(Neuroptics, Irvine, CA), and a KR-1W Wavefront Analyzer
(Topcon Medical Systems, Inc., Oakland, NJ). During the
first visit, pupil diameter was measured before and 20–
30 min after the administration of mydriatic eye drops (1.0%
tropicamide and 10.0% phenylephrine, one drop of each
product, once; in Poland, only 10% phenylephrine is avail-
able). The induction of mydriasis during the preoperative
visit is a routine activity and is performed in every patient
because of the necessity of assessing the posterior segment
of the eye.
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Cataract severity was assessed according to the LOCS III
guidelines. The following four parameters were graded:
nuclear opalescence (NO), nuclear color, cortical cataracts,
and posterior subcapsular cataracts. The use of standard
medications as part of the preparation for cataract surgery
at a given site (e.g., antibiotics and non-steroidal anti-
inflammatory drugs) was recorded in the CRF. Patients eligible
to receive Mydrane could not receive mydriatic eye drops
before surgery. However, the subjects were not prohibited
from receiving concomitant therapy or additional drugs. All
therapeutic decisions were made by the treating physician.
Pupil diameter was measured during cataract surgery
(visit 2) by using a medical ruler. Pupil size measurement
(with 0.5 mm accuracy at least determined by precision of
the used/available measurement instrument) was done with
a medical ruler made of stainless steel (sterilizable).
Each additional drug or medical device used to induce or
maintain mydriasis was recorded in the CRF. Different types
of anesthesia (topical, periorbital, general anesthesia) are
used during cataract surgeries in everyday clinical practice.
Topical and intravenous anesthetics and sedatives can in-
fluence mydriasis. In the phase III Mydrane study mentioned
earlier, the patients received topical anesthesia twice before
surgery.7 Mydrane is an intracameral combination of myd-
riatics and anesthetics that is used for cataract surgery.
Mydrane is a new product and is primarily considered a
mydriatic agent. As this was an observational trial, we did
not standardize how the patients were anesthetized. All an-
esthetics administered during surgery, whether by the sur-
geon or the anesthetist, were reported.
Surgical technique
The surgeons used standard surgical techniques to per-
form cataract surgery. Ophthalmic viscosurgical devices
were used in all departments, according to standard proce-
dures. The use of trypan blue, acetylcholine chloride, or
corticosteroids was noted, and all complications or adverse
reactions were reported by the surgeon just after the end of
each surgery (if applicable).
Endpoints and assessments
The purpose of this study was to evaluate the effect of
Mydrane on the time needed to achieve mydriasis and
mydriasis stability during cataract surgery. Pupil diameter
was measured at the following four key points during cat-
aract surgery: just before the start of surgery, just before
capsulorhexis, just before intraocular lens implantation, and
just before the end of surgery.
Immediately after the end of surgery, the operating sur-
geon’s opinions on the time to obtain mydriasis and my-
driasis stability were assessed on a 5-point Likert scale Each
surgeon was asked to rate the following two statements on
a 5-point scale (strongly agree, somewhat agree, neither
agree nor disagree, somewhat disagree, strongly disagree):
‘‘Mydriasis was obtained in a short time after the adminis-
tration of Mydrane’’ and ‘‘Mydriasis was stable after the
administration of Mydrane.’’
Sample size and statistical methods
The calculated sample size for a population of 278,000
(the estimated number of cataract surgeries performed in
1 year in Poland) is 246. This sample size allows us to
assume that 80% of patients will have pupil dilation higher
or equal to 6 mm, which is in line with expert knowledge
and previous studies. The collected data were analyzed
with descriptive statistical methods by using Microsoft
Excel 2013. Data were expressed as the means and standard
deviations, medians with ranges, or percentages where
appropriate.
Results
Patient flow and baseline characteristics
During 2 weeks 387 patients, who consented to partici-
pate in the study, underwent a full preoperative assessment
and cataract surgery. Pupil dilation to a diameter ‡6 mm was
achieved in 323 patients during the preoperative visit. This
group of patients was eligible to receive Mydrane. Sixteen
patients received mydriatic eye drops before surgery, as
decided by their surgeons, who were unable to examine the
patients previously and thus decided to dilate their pupils to
examine them just before surgery. These patients were not
included in the ‘‘Registry,’’ nor were 64 patients whose
pupils were dilated to a diameter <6 mm before surgery. At
the time of the study, the payer in Poland did not pay for
bilateral surgeries, so we did not have any bilateral opera-
tions. Ultimately, 307 patients at 7 study sites underwent
cataract surgery after Mydrane administration and were
included in the ‘‘Registry.’’ Thus, 83.5% of patients expe-
rienced satisfactory pupil dilatation (defined as ‡6 mm)
during preoperative examination.
Demographics
The majority of patients who underwent surgery were
women (71.7%, n = 220), and the mean age of the total
population was 73.8 – 8.7 years. The median age was 74
years (range, 40–99 years).
Ocular history
Only data pertaining to the eye that was treated were
collected in this study. Based on their medical histories,
29.0% of patients had concomitant eye diseases. The most
common disease was glaucoma, followed by other common
types of eye diseases, age-related macular degeneration
(AMD), and diabetic retinopathy. A history of eye diseases
was reported by 8.5% of patients, whereas histories of eye
surgery and laser therapy were reported by 4.0% and 4.0%
of patients, respectively. A detailed analysis showed that
some patients reported more than one eye disease. The de-
mographics and baseline characteristics of the patients en-
rolled in the study are summarized in Table 1.
Iris color
Iris color in the treated eye was assessed according to the
simplified anthropological Martin scale.15 The eye was de-
scribed as dark (in patients with black-brown, dark-brown,
and brown irises), transient and mixed (in patients with light-
brown, greenish-brown, light-green, dark-gray, and gray irises),
and light (in patients with light-gray, gray-blue, blue, and
light-blue irises). Light eyes were noted in 49.2% (n = 151) of
patients included in the registry, transient and mixed eyes
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were noted in 36.8% (n = 113) of patients, and dark eyes were
noted in 14.0% (n = 43) of patients included in the registry.
Ocular findings (anterior segment)
Specific anterior segment abnormalities were noted in
the study questionnaires. The most common abnormality
was pseudoexfoliation syndrome (PEX), which occurred
in 8.5% patients, followed by iridotomies (2.6%), posterior
synechiae (1.0%), iris atrophy (1.0%), and iris neovascu-
larization (0.3%) (Table 1).
LOCS III grading
For each item, a higher grade was indicative of more
severe disease. Of the 307 patients included in the study,
79.2% (n = 243) had nuclear opacities ‡LOCS NO3.
General diseases
At least one general disease was noted in 92.8% of pa-
tients. Most patients had more than one general disease, and
a total of 587 diseases were reported by the study popu-
lation. The most common general disease was arterial
hypertension, which affected 78.5% (n = 241) of patients,
followed by other chronic diseases, which affected 74.3%
(n = 228) of patients; diabetes, which affected 23.5% (n = 72)
of patients; prostate disease, which affected 9.4% of the total
study population and 33.0% (n = 29) of male patients; and
depression, which affected 5.5% (n = 17) of patients. Thirty
percent of patients with diabetes were treated with insulin.
Anesthesia
Mydrane was supplemented with only anesthetic eye drops
in 86% (n = 264) of cataract surgeries. Additional topical
anesthetics were used in 7.8% (n = 24) of surgeries. Peri-
orbital anesthesia was applied in 6.5% (n = 20) of surgeries,
and general anesthesia was used in 0.7% (n = 2) of surgeries.
Drugs were administered by the anesthetist in 78% of sur-
geries. The most frequently used drug was midazolam
[67.4% (n = 207)], followed by fentanyl [59.9% (n = 184)],
lignocaine [21.8% (n = 67)], and other drugs [10.1% (n = 31)].
Outcomes
The cataract surgeries for the aforementioned 307 patients
were performed by 58 surgeons.
The mean and median pupil diameters in the entire study
population were:
 2.3 – 1.1 mm and 2.0 mm (range, 1.0–8 mm), respec-
tively, just before the start of surgery,
 7.0 – 1.0 mm and 7.0 mm (range, 4.0–9.5 mm), respec-
tively, just before capsulorhexis,
 6.9 – 1.2 mm and 7.0 mm (range, 1.0–10 mm), respec-
tively, just before intraocular lens implantation,
 6.6 – 1.4 mm and 7.0 mm (range, 2.5–11 mm), respec-
tively, just before the end of surgery.
In post hoc analysis, we used a pupil diameter of 6 mm as
a cut-off point to assess some secondary efficacy parame-
ters (the percentages of patients in whom a pupil diameter
‡6 mm was achieved at defined time points during surgery).
A pupil diameter ‡6 mm was achieved in 91.9% (n = 282)
of patients just before capsulorhexis, 87.6% (n = 269) of
patients just before lens implantation, and 75.2% (n = 231)
of patients just before the end of surgery.
In 88.0% of cases, cataract surgery was performed, and
mydriasis was achieved without the use of any additional
drugs or medical devices. In the remaining 12.0% cases,
epinephrine injection was the method most commonly used
to achieve mydriasis. Epinephrine was used to maintain
mydriasis in <0.5% surgeries. Mechanical expanders were
used twice in the study population (1 Malyugin ring and 1
Table 1. Ocular History and Anterior
Segment Findings






Dry AMD 13 4.2
Wet AMD 6 2.0
Diabetic retinopathy 4 1.3
Other 36 11.7





Corneal disease 11 3.6
Uveitis 2 0.7
Retinal detachment 1 0.3
Other 14 4.6














Anterior segment 8 2.6
Retinal photocoagulation 4 1.3
Conditions identified during
anterior segment assessment N % out of n = 307
Pseudoexfoliation syndrome 26 8.5
Iris atrophy 3 1.0
Iridotomy(-ies) 8 2.6
Iris neovascularization 1 0.3
Posterior synechiae 3 1.0
AMD, age-related macular degeneration.
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spatula). Additional analyses were performed in the following
two groups: patients in whom no additional drugs or medical
devices were used to achieve or maintain mydriasis during
cataract surgery and patients in whom additional drugs or
medical devices were used to achieve or maintain mydriasis
during cataract surgery. In the group of patients in whom no
additional drugs or medical devices were used, the mean and
median pupil diameters just before capsulorhexis were
7.1 – 0.96 mm and 7 mm (range, 4.0–9.5 mm), respectively
(Table 2).
A pupil diameter ‡6 mm was achieved in 95.2% of
patients just before capsulorhexis, in 91.4% of patients just
before lens implantation, and in 79.0% of patients just
before the end of surgery.
In the group of patients in whom additional drugs or
medical devices were used, the mean and median pupil di-
ameters just before capsulorhexis were 6.11 – 1.16 mm and
6 mm (range, 4.5–9.0 mm), respectively (Table 2).
A pupil diameter ‡6 mm was achieved in 66.7% of
patients just before capsulorhexis, 63.9% of patients just
before lens implantation, and 52.8% of patients just before
the end of surgery.
We asked the 58 surgeons whether they agreed with the
statement ‘‘Mydriasis was obtained in a short time after the
administration of Mydrane’’ and found that they agreed with
this statement after 92.2% (283/307) of surgeries (strongly
agreed, 74.3%; somewhat agreed, 17.9%). The surgeons dis-
agreed with this statement after 6.5% of surgeries (some-
what disagreed, 5.5%; strongly disagreed, 1.0%) and had no
opinion regarding this statement (neither agreed nor dis-
agreed) after 1.3% of surgeries (Fig. 1).
We found that after 88.2% of surgeries, the surgeons
agreed with the statement ‘‘Mydriasis was stable after the
administration of Mydrane’’ (strongly agreed, 71.3%; some-
what agreed, 16.9%). However, the surgeons disagreed with
this statement after 8.2% of surgeries (somewhat disagreed,
7.2%; strongly disagreed, 1.0%) and had no opinion re-
garding this statement (neither agreed nor disagreed) after
3.6% of surgeries (Fig. 2).
Only one adverse drug reaction occurred during the
surgeries. Sudden miosis occurred in one patient at the
beginning of surgery, just after the injection of Mydrane,
and receded spontaneously. Intraoperative complications
occurred in 3.5% (n = 11) of patients. The most frequent
complication was a posterior capsule tear. Anterior vitrec-
tomy was performed in 0.6% (n = 2) of patients.
Discussion
Surgeons must obtain a very good postoperative result in
the majority of patients who undergo contemporary cataract
surgery. An increased emphasis has been placed on using
local anesthesia and administering drugs intracamerally, and
studies have shown that intracameral drug administration
induces rapid and safe mydriasis.2,7,8 Studies have focused
not only on pupil dilators but also on anti-inflammatory
agents and means of maintaining mydriasis with med-
ications injected intracamerally.16 The introduction and
Table 2. Mean and Median Pupil Diameters in the Subgroups
Mean [mm] SD [mm] Median [mm] Range [mm] > -6 mm [%]
The mean and median pupil diameters in the group of patients in whom no additional drugs or medical devices were used
Before the start 2.33 1.1 2.0 1.0–8.0 —
Before capsulorexis 7.1 0.96 7.0 4.0–9.5 95.2
Before intraocular lens implantation 7.05 1.13 7.0 1.0–10.0 91.4
Before the end of surgery 6.72 1.31 7.0 7.0–11.0 79.0
The mean and median pupil diameters were in the group of patients in whom additional drugs or medical devices were used
Before the start 2.14 1.01 2.0 1.0–6.0 —
Before capsulorexis 6.11 1.16 6.0 4.5–9.0 66.7
Before intraocular lens implantation 6.15 1.17 6.0 3.5–8.0 63.9
Before the end of surgery 5.91 1.44 6.0 2.5–8.0 52.8
SD, standard deviation.
FIG. 1. Surgeons’ opinions regarding
the time needed to achieve mydriasis after
Mydrane administration.
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registration of the first ready-to-use combined mydriatic and
anesthetic, which can be intracamerally injected, have pro-
vided surgeons with a new tool. A randomized controlled
trial has shown that Mydrane causes pupil enlargement and
anesthetic effects. However, each of the aforementioned
studies used strict inclusion and exclusion criteria. Thus, a
Polish research group was created to study the effects of
Mydrane during cataract surgeries in a non-selected patient
population. Patient enrolment in this study was facilitated by
the use of the so-called ‘‘queue list’’ of a public payer in
Poland. An explanation of the logistics of cataract surger-
ies in Poland exceeds the framework of this publication.
However, it is important to emphasize that all of these
factors influence patient flow (especially admission to the
hospital and cancellation of surgery).
The surgeon’s decision regarding how the pupil is dilated
may be determined by many factors (e.g., clinical trial re-
sults, drug accessibility, and price). The most important
factors are surgeon experience and surgeon opinions about
products. Thus, we decided to ask each surgeon’s opinion on
the time needed to achieve mydriasis and mydriasis stabil-
ity. To minimize bias, we asked the operating physicians
to fill out the forms immediately after the procedure, as any
emotions they experienced about the case would not have
subsided at that point in time.
Our study had some limitations. The study was an open-
label, non-randomized investigation without a control
group. In addition, during the surgeries in which additional
medicines were used to achieve mydriasis, pupil diameter
was not measured before the injection of epinephrine. Thus,
pupil dilation may have been achieved by the injection
of both drugs (Mydrane and epinephrine) in these cases.
Due to the observational nature of the study, it was necessary
to limit the amount of data collected. Therefore, no data were
collected on the type of viscoelastic, surgical settings, and the
time savings. The length requirements do not allow us to
present in this article the results of all the analyses we con-
ducted. Consequently, we presented the results concerning
only the primary and secondary objectives of the study.
The study also had many advantages. It was conducted at
seven university hospitals. In addition, we collected data
that reflected many surgeons’ opinions; in particular, a total
of 58 operating surgeons who performed 307 surgeries par-
ticipated in this study. The study was conducted in academic
hospitals. Among the operating doctors were both doctors
with extensive surgical experience and less experienced
doctors. According to the Polish law, a non-interventional
study must not affect standard clinical practice. In the CRFs,
we did not collect information about the operating doctors
and their surgical experience. That approach ensured ano-
nymity. At the same time, the sample size of the sample
allowed us to generalize the results to the entire population.
We investigated the use of Mydrane under conditions to
which actual populations of patients undergoing cataract
surgery, who, in this study, were chosen without the use
of inclusion or exclusion criteria, are subjected. Real-life
studies have high generalizability, because in contrast to
randomized controlled trials, they provide data on real-life
situations rather than a specific set of patients who were
selected in accordance with strict and controlled criteria.17
Almost all the patients enrolled in the study had at least
one concomitant general disease, and almost one-third
had concomitant eye diseases. Patients with diabetes, PEX,
and prostate diseases treated with a-blockers and other
drugs that increase the risk of intraoperative floppy-iris
syndrome14,18,19 were included in the study. It is worth
noting that our study population included patients with se-
vere cataracts, because more than 45% of the patients
enrolled in the study had NO, which corresponds to an
LOCS III grade ‡NO4.
We also assessed secondary efficacy parameters by deter-
mining the percentage of patients in whom a pupil diameter
‡6 mm was achieved at defined time points during surgery.
A study by Donnenfeld et al.,16 which was published in the
May 2017 issue of Journal of Cataract & Refractive Surgery
(JCRS), stated that the U.S. Food and Drug Administration
defines intraoperative miosis as a pupil diameter smaller
than 6.0 mm at any time during surgery. Thus, our assump-
tion was consistent with the guidelines of the U.S. Food and
Drug Administration. It is worth emphasizing that such mi-
osis was reported in only 8.1% (n = 25) of patients before
capsulorhexis and in 12.4% (n = 38) of patients before lens
implantation. Mydriasis was achieved after a single injection
of Mydrane without any preoperative mydriasis in a real-life
patient population. Acetylcholine chloride was used to induce
miosis in 6% (n = 19) of patients at the end of surgery.
Surgeons consider stable dilatation the most important
factor in cataract surgery.1 There are no standardized ques-
tionnaires to assess the surgeons’ opinion on the speed of
pupil dilatation and on the stability of mydriasis during
FIG. 2. Surgeons’ opinions regarding
mydriasis stability.
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surgery. Our study is innovative in this respect. To collect
surgeons’ opinions, we used a Likert scale questionnaire,
which is used for used for measuring opinions and attitudes,
because we need a short, reliable tool that will not interfere
with the work in the operating theater. Asking the doctors
two questions, directly in the operating room just after the
surgery, allowed us to eliminate the perceptual error. In
almost 90% of cases, the surgeons confirmed that the my-
driasis obtained by using Mydrane was fast and stable.
A mean pupil diameter of 7.0 mm immediately before
capsulorhexis was achieved in the population of patients
with pupils assumed to be satisfactory during a preoperative
examination; in our study, the threshold for assuming pupils
to be satisfactorily dilated during the preoperative exami-
nation was 6 mm (1 mm smaller than that reported in the
aforementioned randomized study).
In conclusion, the study showed that the mydriasis obtained
with an intracameral fixed, ready-to-use combination of tro-
picamide, phenylephrine, and lidocaine (Mydrane) during
cataract surgery in a non-selected patient population is fast
and stable. Therefore, the results of the study may be appli-
cable to a broad group of patients undergoing cataract surgery.
The results are based on both pupil diameter measurements
performed during cataract surgery and surgeons’ opinions.
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